Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply
- PMID: 37243470
- DOI: 10.1111/apt.17514
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply
Comment on
-
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.Aliment Pharmacol Ther. 2023 Jun;57(11):1290-1298. doi: 10.1111/apt.17421. Epub 2023 Feb 27. Aliment Pharmacol Ther. 2023. PMID: 36849714
-
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.Aliment Pharmacol Ther. 2023 Jun;57(12):1469-1470. doi: 10.1111/apt.17439. Aliment Pharmacol Ther. 2023. PMID: 37243472 No abstract available.
References
REFERENCES
-
- Hanzel J, Drobne D. Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring. Aliment Pharmacol Ther. 2023;57:1469-70.
-
- Fumery M, Nancey S, Filippi J, Altwegg R, Hébuterne X, Boshetti G, et al. Effectiveness of golimumab intensification in ulcerative colitis: a multicentric prospective study. Aliment Pharmacol Ther. 2023;57:1290-8.
-
- Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Schneeweiss S, Kim SC. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. Gut. 2022;71:1781-9.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical